The Future of Biopharma

by David Gemmell | December 6, 2022


The Chemical Engineering magazine has published its third article of the biopharmaceutical manufacturing series, written by David Gemmell.

In the article “The Future of Biopharma” he explores why the biopharmaceutical industry is driving towards achieving intensified, connected, or continuous, manufacturing processes. He discusses the challenges that must be overcome to be able to operate a controllable process capable of providing high quality therapeutics.

Want to learn more about how the future of Biopharma could look like? Read the third article of the biopharmaceutical manufacturing series here: The Future of Biopharma

David Gemmell has been working for MilliporeSigma for over six years. David is currently employed with the Technical & Scientific Solutions MSAT (Manufacturing Sciences & Technology) department. David’s primary focus is on optimising or troubleshooting downstream purification unit operations for customers, focusing on both novel and traditional modalities, across all purification technologies. He is also the High Temperature Short Time Subject Matter Expert for upstream viral risk mitigation. At University David obtained a BEng (Hons) in Chemical Engineering and an MSc in Advanced Chemical & Process Engineering. His early career was based in the nuclear and power generation sectors before moving into biopharmaceutical and life sciences.

Related Posts

Vaccines are entering a new era and recently we hosted a virtual event to share insights on market trends, challenges, and potential solutions regarding the future of vaccine manufacturing.

In this On-Demand version of the presentations, key opinion leaders from [geot_filter region="north-america"...

Can we change the Biopharma Supply Chain Game so that Everyone Gets a Trophy?

There is a popular board game based on a global disease outbreak that is generally rated 5 stars. ...

mRNA Process and Cost Modeling: A Tool to Optimize Process Development

mRNA technology has proven to enable rapid drug development. mRNA is an attractive modality to work with because...

How to model the Economics of Vaccine Manufacturing

This whitepaper describes the development and use of a cost model encompassing capital, labor, materials, consumables, and other...

Want to Increase your pDNA purity and Yields? Optimize Your pDNA Downstream Purification Process

Get a step-by-step overview of the plasmid DNA manufacturing process and the challenges in pDNA downstream purification, for...

Curious to learn more on PAT, Raman Spectroscopy, and Chemometrics?

Are you curious about Process Analytical Technologies (PAT), Raman spectroscopy, chemometrics and Raman applications in bioprocessing? Watch this...

Scroll to Top